Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted) (2014 - 2026)
Soleno Therapeutics (SLNO) reported EPS (Weighted Average and Diluted) of $0.59 for Q1 2026, up 162.11% year-over-year from $0.23 in Q1 2025, and down 29.76% quarter-over-quarter from $0.84 in Q4 2025.
Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted) (2014 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has 12 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.59 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.59, up 162.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.81 (up 138.92% YoY), and the FY2025 annual result was $0.39, up 108.9% from the prior year.
- EPS (Weighted Average and Diluted) fell to $0.59 in Q1 2026 per SLNO's latest filing, from $0.84 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.84 in Q4 2025 and troughed at -$1.83 in Q3 2024.
- A 5-year average of -$0.52 and a median of -$0.65 in 2022 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) sank 548.28% in 2024, then surged 164.62% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.56 in 2022, then soared by 151.79% to $0.29 in 2023, then slumped by 548.28% to -$1.3 in 2024, then surged by 164.62% to $0.84 in 2025, then dropped by 29.76% to $0.59 in 2026.
- Business Quant data shows SLNO's EPS (Weighted Average and Diluted) at $0.59 in Q1 2026, $0.84 in Q4 2025, and $0.47 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 0.59 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.59 |
| Dec 31, 2025 | 0.84 |
| Sep 30, 2025 | 0.47 |
| Jun 30, 2025 | -0.09 |
| Mar 31, 2025 | -0.95 |
| Dec 31, 2024 | -1.30 |
| Sep 30, 2024 | -1.83 |
| Jun 30, 2024 | -0.57 |
| Mar 31, 2024 | -0.59 |
| Dec 31, 2023 | 0.29 |
| Sep 30, 2023 | -0.95 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -0.88 |
| Dec 31, 2022 | -0.56 |
| Sep 30, 2022 | -0.65 |
| Jun 30, 2022 | -0.72 |
| Mar 31, 2022 | -1.07 |
| Dec 31, 2021 | -0.53 |
| Sep 30, 2021 | -1.53 |
| Jun 30, 2021 | -0.14 |